Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry

Autoři	SALMANTON-GARCIA Jon MARCHESI Francesco MACKENZIE Erica HERAS-FERNANDO Inmaculada FALCES-ROMERO Iker VENA Antonio GARCIA-VIDAL Carolina WEINBERGEROVÁ Barbora SGHERZA Nicola PIUKOVICS Klara MENDEZ Gustavo Adolfo LEOTTA Dario LOPEZ-GARCIA Alberto FARINA Francesca ERBEN Nurettin BILGIN Yavuz M BIERNAT Monika M PETZER Verena MAGLIANO Gabriele DRGONA Lubos VISEK Benjamin SOTO-SILVA Andres SAMARKOS Michail NAVRATIL Milan LAHMER Tobias FRACCHIOLLA Nicola S VINH Donald C PREZIOSO Lucia PANTIC Nikola KHOSTELIDI Sofya KHEDR Reham Abdelaziz EISA Noha DARGENIO Michelina BUQUICCHIO Caterina PINCZES Laszlo Imre PAPA Mario Virgilio GARCIA-RAMIREZ Patricia DABROWSKA-IWANICKA Anna CUCCARO Annarosa COLOVIC Natasa CERNAN Martin JENS Van Praet VALKOVIC Toni PLANTEFEVE Gaetan MERELLI Maria LABRADOR Jorge KOLDITZ Martin GLENTHOJ Andreas ESPIGADO Ildefonso ERDEM Simge DROZD-SOKOLOWSKA Joanna DELIA Mario CERCHIONE Claudio CATTANEO Chiara BATINIC Josip AVENDANO Alejandro ALMASARI Ahlam PRIN Romane NAPPI Davide MUSTO Pellegrino HERSBY Ditte Stampe ARELLANO Elena CALLEJAS-CHARAVIA Marta VARRICCHIO Gina MITROVIC Mirjana ANASTASOPOULOU Amalia N WOLF Dominik CORDOBA Raul ROMANO Alessandra AIELLO Tommaso Francesco BAVASTRO Martina LIMONGELLI Alessandro GIORDANO Antonio BRUNETTI Sara Caterina NGUYEN Kevin LUKAS Van Der Ven PAGANO Livio CORNELY Oliver A
Rok publikování	2026
Druh	Recenzovaný odborný článek
Časopis / Zdroj	OPEN FORUM INFECTIOUS DISEASES
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://academic.oup.com/ofid/article/13/3/ofag099/8501346?login=true
Doi	https://doi.org/10.1093/ofid/ofag099
Klíčová slova	hematological malignancy; human metapneumovirus; neglected; opportunistic infection; real-world data
Popis	Background Human metapneumovirus (hMPV) is an increasingly recognized respiratory pathogen in immunocompromised patients, but its impact in haematological malignancies is poorly defined. Unlike influenza or SARS-CoV-2, hMPV has no specific treatment or vaccine, contributing to underdiagnosis and underestimation of its clinical relevance.Method We performed a multicentre retrospective cohort study within the Epidemiology of COVID-19 in patients with hematological malignancies: A European Haematology Association Survey/ Epidemiology of respiratory viral infections in patients with hematological malignancies: A European Haematology Association Survey registry of haematological patients with hMPV (January 2023-December 2024), comparing clinical features and outcomes with matched influenza and SARS-CoV-2 cohorts.Results The study included 130 patients with hMPV. Median age was 58.5 years; 57% were male. Plasma cell neoplasms (25%), lymphoma (23%), and acute myeloid leukemia (20%) were the most common hematological malignancies. Hospitalization occurred in 64%, intensive care unit (ICU) admission in 19%, and 30-day mortality was 8%. Most cases (73%) received supportive care only. Secondary infections were common (24%). Chronic renal disease significantly increased mortality risk (hazard ratio 20.9 11.05, P = .014). Compared with influenza and SARS-CoV-2, hMPV patients had comparable severity and outcomes, with 18.5% ICU admission rates versus 25.9% for influenza (P = .316) and 20.9% versus 4.7% for SARS-CoV-2 (P = .006), and 30-day mortality of 5.6% versus 11.1% for influenza (P = .489) and 7.0% versus 2.3% for SARS-CoV-2 (P = .277), yet received fewer targeted interventions.Conclusions hMPV causes clinically significant disease in patients with hematological malignancy, often necessitating hospital and ICU care, and leading to mortality. In the absence of specific treatments or vaccines, this virus remains an underrecognized pathogen in patients with hematological malignancy. Enhanced clinical awareness and investment in diagnostics, prevention, and therapeutics are needed.